Sample code Sex Age CD4 RNA log PI treatment history NNRTI treatment history NRTI treatment history
TC002a Female 36 9 5.07 Saquinavir - Lamivudine, Stavudine
TC106a Female 36 81 3.94 Saquinavir - Lamivudine, Stavudine
TC006b Male 44 441 2.61 - - Didanosine
TC050b Male 44 335 2.68 - - Didanosine
TC008c Male 36 34 3.15 Saquinavir - Lamivudine, Stavudine
TC118c Male 36 81 <2.6   Efavirenz Lamivudine, Stavudine
TC215c Male 36 167 4.04   Nevirapine Lamivudine, Stavudine
TC045d Male 35 155 4.19 Nelfinavir - Lamivudine, Zidovudine
TC201d Male 35 54 5.50   Nevirapine Lamivudine, Stavudine
TC114e Male 32 264 5.32 NA NA NA
TC200e Male 32 249 5.99 NA NA NA
TC117f Female 37 22 5.21 NA NA NA
TC242f Female 37 245 4.01 NA NA NA
TC003 Male 46 81 5.02 Indinavir - Lamivudine, Stavudine
TC012 Female 36 244 5.42 Indinavir Nevirapine Lamivudine, Stavudine
TC013 Male 61 3 2.58 Nelfinavir - Zidovudine/lamivudine
TC041 Female 16 75 2.88 - Nevirapine Zidovudine/lamivudine
TC049 Male 43 15 5.07 Indinavir Nevirapine Didanosine, Stavudine
TC052 Female 42 33 5.43 - Nevirapine Lamivudine, Stavudine
TC056 Female 33 18 4.97 Saquinavir Nevirapine Zidovudine/lamivudine
TC059 Male N/A 148 4.82 Amprenavir Efavirenz Zidovudine/lamivudine
TC060 Female 42 301 3.89 Indinavir Efavirenz Didanosine
TC070 Male 50 25 5.47 Saquinavir - Zidovudine, Didanosine
TC109 Female 45 337 4.95 - Nevirapine Stavudine, Didanosine
TC110 Male 33 111 4.84 Indinavir - Zidovudine, Lamivudine
TC111 Female 32 201 4.97 NA NA NA
TC113 Male 35 323 3.12 NA NA NA
TC203 Male 49 160 5.50 Saquinavir - Zidovudine, Lamivudine
TC204 Female 45 459 4.45 - Nevirapine Stavudine, Didanosine
TC206 Female 41 196 4.90 Nelfinavir Nevirapine Lamivudine, Zidovudine
TC216 Female 33 16 4.92 Saquinavir Nevirapine Zidovudine/lamivudine
TC238 Female 38 290 5.35 Indinavir, Amprenavir Nevirapine Stavudine, Lamivudine
NA, not available
a-f Samples with the superscripted letters are from a same patient in different time points.
Zidovudine/lamiuvudine refers to a full dose combination of the two drugs as “Combavir”
Table 1: Demographic characteristics, baseline features and drug history of the subjects in Zimbabwe.